Literature DB >> 16374627

Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.

R de Vries1, G M Dallinga-Thie, A J Smit, B H R Wolffenbuttel, A van Tol, R P F Dullaart.   

Abstract

AIM/HYPOTHESIS: The plasma activity of phospholipid transfer protein (PLTP), which has putative pro- and anti-atherogenic roles in lipoprotein metabolism, is increased in type 2 diabetes mellitus. We analysed the relationship between carotid artery intima-media thickness (IMT), an established marker of atherosclerosis, and PLTP activity in diabetic patients and control subjects.
METHODS: The IMT (mean of three segments in both carotid arteries by ultrasonography), clinical variables, plasma PLTP activity (phospholipid vesicle-HDL system), lipoproteins, C-reactive protein and insulin were measured in 87 non-smoking men and women, who had type 2 diabetes mellitus, no cardiovascular disease, and were not on insulin or lipid-lowering medication, and in 83 age-matched control subjects.
RESULTS: In diabetic patients, carotid IMT (p=0.02), pulse pressure (p=0.003), plasma PLTP activity (p<0.001), triglycerides (p=0.01), C-reactive protein (p<0.01) and insulin (p<0.001) were higher, whereas HDL cholesterol was lower (p<0.001) than in control subjects. Multiple stepwise linear regression analysis demonstrated that in type 2 diabetic patients IMT was independently associated with age (p<0.001), sex (p=0.001), pulse pressure (p=0.003), plasma PLTP activity (p=0.03) and HDL cholesterol (p=0.03), but not with very low density lipoprotein+LDL cholesterol, triglycerides, C-reactive protein and insulin (all p>0.20). The relationship between plasma PLTP activity and IMT was not significant in control subjects. CONCLUSIONS/
INTERPRETATION: Plasma PLTP activity is a positive determinant of IMT in type 2 diabetes mellitus, suggesting that high PLTP activity is involved in accelerated atherosclerosis in this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16374627     DOI: 10.1007/s00125-005-0088-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

1.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.

Authors:  D H O'Leary; J F Polak; R A Kronmal; T A Manolio; G L Burke; S K Wolfson
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

2.  Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein.

Authors:  S Riemens; A van Tol; W Sluiter; R Dullaart
Journal:  Atherosclerosis       Date:  1998-09       Impact factor: 5.162

3.  Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus.

Authors:  K C B Tan; S W M Shiu; Y Wong
Journal:  Eur J Clin Invest       Date:  2003-04       Impact factor: 4.686

4.  Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus.

Authors:  P H N Oomen; A van Tol; H Hattori; A J Smit; L M Scheek; R P F Dullaart
Journal:  Diabet Med       Date:  2005-06       Impact factor: 4.359

5.  Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism.

Authors:  R P Dullaart; W J Sluiter; L D Dikkeschei; K Hoogenberg; A Van Tol
Journal:  Eur J Clin Invest       Date:  1994-03       Impact factor: 4.686

6.  Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity.

Authors:  Martina Schneider; Bruno Vergès; Alexis Klein; Elizabeth R Miller; Valérie Deckert; Catherine Desrumaux; David Masson; Philippe Gambert; Jean-Marcel Brun; Jamila Fruchart-Najib; Denis Blache; Joseph L Witztum; Laurent Lagrost
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

7.  Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma.

Authors:  H Speijer; J E Groener; E van Ramshorst; A van Tol
Journal:  Atherosclerosis       Date:  1991-10       Impact factor: 5.162

8.  High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease.

Authors:  Axel Schlitt; Christoph Bickel; Prathima Thumma; Stefan Blankenberg; Hans J Rupprecht; Juergen Meyer; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-08-28       Impact factor: 8.311

9.  Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study.

Authors:  Ronald M A Henry; Piet J Kostense; Annemieke M W Spijkerman; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Otto Kamp; Nico Westerhof; Lex M Bouter; Coen D A Stehouwer
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

10.  Human plasma phospholipid transfer protein causes high density lipoprotein conversion.

Authors:  M Jauhiainen; J Metso; R Pahlman; S Blomqvist; A van Tol; C Ehnholm
Journal:  J Biol Chem       Date:  1993-02-25       Impact factor: 5.157

View more
  26 in total

1.  Impact of site-specific N-glycosylation on cellular secretion, activity and specific activity of the plasma phospholipid transfer protein.

Authors:  John J Albers; Joseph R Day; Gertrud Wolfbauer; Hal Kennedy; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-04-16

Review 2.  Genetics and molecular biology: phospholipid transfer protein in atherogenesis.

Authors:  David Akopian; Jheem D Medh
Journal:  Curr Opin Lipidol       Date:  2006-12       Impact factor: 4.776

3.  PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.

Authors:  Daniel Seung Kim; Amber A Burt; Jane E Ranchalis; Simona Vuletic; Tomas Vaisar; Wan-Fen Li; Elisabeth A Rosenthal; Weijiang Dong; Jason F Eintracht; Arno G Motulsky; John D Brunzell; John J Albers; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2015-05-25       Impact factor: 5.922

Review 4.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

Review 5.  Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases.

Authors:  Xian-Cheng Jiang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Genetic and nongenetic sources of variation in phospholipid transfer protein activity.

Authors:  Gail P Jarvik; Ramakrishnan Rajagopalan; Elisabeth A Rosenthal; Gertrud Wolfbauer; Laura McKinstry; Aditya Vaze; John Brunzell; Arno G Motulsky; Deborah A Nickerson; Patrick J Heagerty; Ellen M Wijsman; John J Albers
Journal:  J Lipid Res       Date:  2009-11-02       Impact factor: 5.922

7.  Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2009-04-17       Impact factor: 5.162

8.  Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes.

Authors:  Yi Luo; Lorraine Shelly; Thomas Sand; Benjamin Reidich; George Chang; Mary Macdougall; Marie-Claire Peakman; Xian-Cheng Jiang
Journal:  J Pharmacol Exp Ther       Date:  2009-11-20       Impact factor: 4.030

9.  Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.

Authors:  Sander J Robins; Asya Lyass; Robert W Brocia; Joseph M Massaro; Ramachandran S Vasan
Journal:  Atherosclerosis       Date:  2013-02-18       Impact factor: 5.162

10.  Plasma PLTP activity is inversely associated with HDL-C levels.

Authors:  Xueying Chen; Aijun Sun; Ather Mansoor; Yunzeng Zou; Junbo Ge; Jason M Lazar; Xian-Cheng Jiang
Journal:  Nutr Metab (Lond)       Date:  2009-11-30       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.